Simulations Plus Inc.
Simulations Plus Inc.
01/08/2024 | Press release | Distributed by Public on 01/08/2024 23:15
Simulations Plus Releases DILIsym® X
- August 1, 2024
- Press Release
Simulations Plus Releases DILIsym® X
Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, has released the latest version of its flagship quantitative systems toxicology (QST) platform, DILIsym® version X.
"Modeling and predictions regarding drug efficacy are critical in the drug development process-but so are predictions regarding safety," said Dr. Brett Howell, President of) Quantitative Systems Pharmacology (QSPSolutions at Simulations Plus. "We know there is often a gap between preclinical and clinical research toxicology results, but DILIsym is designed to help researchers identify potential DILI risks and, when appropriate, design dosing strategies that can mitigate or eliminate possible hazards. With the enhanced processing speed and improved user interface offered by DSX, clients get crucial insight into the safety of their drug candidate faster and more easily than ever before."
Branded as DSX™, the software is designed to support key drug development decisions by predicting potential drug-induced liver injury (DILI) risks. These predictions can guide go/no-go decisions, or the need to modify dosages, which are vital to avoiding costly failed clinical trials.
Dr. Scott Q. Siler, Chief Scientific Officer of QSP Solutions at Simulations Plus, added, "DSX will greatly enhance our clients' and our consulting group's ability to quickly generate population-level liver safety results that impact drug development decisions. This faster turnaround time means fewer delays between critical safety decision points, ensuring safe new drugs get to patients as rapidly as possible while unsafe drug candidates can be discarded earlier in the costly development process."
DSX offers a completely redesigned interface, tested by clients and consultants, that includes both command line and graphical interface options as well as a licensing option that enables scale-up on local or cloud cluster configurations. Four new exemplar compounds are included in this version of the software, as well as two new simulated populations that include variability in susceptibility to liver injury and biomarker-related parameters (ALT and bilirubin).